All lobbying filings

THE MCMANUS GROUP

Lobbying for EMD SERONO, INC. · Client is a biopharmaceutical company.

Filing 4th Quarter - Termination

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

HR 4639
Infertility Treatment Affordability Act of 2025
S 839
Safeguarding Honest Speech Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 2

Health Issues

General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments, including the Infertility Treatment Affordability Act (H.R. 4639).

Medicare/Medicaid

Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.